{"id":55584,"date":"2026-01-27T17:30:49","date_gmt":"2026-01-27T09:30:49","guid":{"rendered":"https:\/\/flcube.com\/?p=55584"},"modified":"2026-01-27T17:30:50","modified_gmt":"2026-01-27T09:30:50","slug":"boehringer-ingelheim-licenses-simceres-sim0709-bispecific-for-inflammatory-bowel-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55584","title":{"rendered":"Boehringer Ingelheim Licenses Simcere\u2019s SIM0709 Bispecific for Inflammatory Bowel Disease"},"content":{"rendered":"\n

Boehringer Ingelheim<\/strong> and Simcere Pharmaceutical Group<\/strong> (HKG: 2096<\/a>) announced a licensing and collaboration agreement to co\u2011develop SIM0709<\/strong>, a preclinical\u2011stage TL1A\/IL\u201123p19 bispecific antibody<\/strong>, for the treatment of Inflammatory Bowel Disease (IBD)<\/strong>. Boehringer Ingelheim acquires global rights outside Greater China, while Simcere retains rights in its home market.<\/p>\n\n\n\n

Deal Structure & Financial Terms<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Simcere Pharmaceutical Group (2096.HK)<\/td><\/tr>
Licensee<\/strong><\/td>Boehringer Ingelheim<\/td><\/tr>
Asset<\/strong><\/td>SIM0709 (TL1A\/IL\u201123p19 bispecific antibody)<\/td><\/tr>
Development Stage<\/strong><\/td>Preclinical<\/td><\/tr>
Indication<\/strong><\/td>Inflammatory Bowel Disease (IBD)<\/td><\/tr>
Territory<\/strong><\/td>Global rights outside Greater China<\/td><\/tr>
Upfront Payment<\/strong><\/td>Undisclosed<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to EUR\u202f1.058\u202fbillion (development, regulatory, commercial)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered royalties on net sales outside Greater China<\/td><\/tr>
Technology<\/strong><\/td>Simcere\u2019s multi\u2011antibody platform (long\u2011acting humanized bispecific)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n